A systematic approach to biomarker discovery
Author Information
Author(s): Lisa H Butterfield, Mary L Disis, Bernard A Fox, Peter P Lee, Samir N Khleif, Magdalena Thurin, Giorgio Trinchieri, Ena Wang, Jon Wigginton, Damien Chaussabel, George Coukos, Madhav Dhodapkar, Leif Håkansson, Sylvia Janetzki, Thomas O Kleen, John M Kirkwood, Cristina Maccalli, Holden Maecker, Michele Maio, Anatoli Malyguine, Giuseppe Masucci, A Karolina Palucka, Douglas M Potter, Antoni Ribas, Licia Rivoltini, Dolores Schendel, Barbara Seliger, Senthamil Selvan, Craig L Slingluff Jr, David F Stroncek, Howard Streicher, Xifeng Wu, Benjamin Zeskind, Yingdong Zhao, Mai-Britt Zocca, Heinz Zwierzina, Francesco M Marincola
Hypothesis
The task force aims to identify best practices for immune monitoring and develop strategies for novel biomarker identification.
Conclusion
The task force is focused on improving the identification and validation of biomarkers to enhance cancer immunotherapy.
Supporting Evidence
- The task force aims to improve immune monitoring procedures.
- Standardized assays are necessary for inter-trial comparisons.
- Novel biomarkers could enhance understanding of cancer immune biology.
Takeaway
Scientists are trying to find better ways to measure how well cancer treatments work by discovering new markers that can help predict patient responses.
Methodology
The task force is organized into working groups focusing on novel assays and biomarker validation.
Limitations
Current monitoring strategies do not reliably predict treatment efficacy due to small study sizes and lack of standardization.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website